Serotonin type 3 receptor (5-HT3R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis
Neuropsychopharmacology · 2026-09 · 51 (10) · 1891-1897
DOI: 10.1038/s41386-026-02467-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neuropsychopharmacology, online erschienen am 17.06.2026. Verfasst von Megan R Mayer und 3 weiteren Autor:innen. Beteiligte Einrichtung: New York State Psychiatric Institute, New York, NY, USA. Hauptthemen laut MEDLINE: Schizophrenia, Serotonin 5-HT3 Receptor Antagonists, Cognition Disorders. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: internal funding (NYSPI) to JTK.
Abstract (Originalsprache)
While both dopamine type 2 receptor antagonists and the muscarinic M1R M1/M4R agonist xanomeline (KarXT) have shown to be effective in treating positive and total symptoms of schizophrenia, full or partial treatment resistance is common, particularly for negative symptoms and cognitive impairment associated with schizophrenia (CIAS). Based on the concept of targeting excitatory-inhibitory (E/I)-imbalance, serotonin type 3 receptor (5-HT3R) antagonists may have utility as an adjunctive treatment for residual symptoms in schizophrenia. We present a meta-analysis of 5-HT3R antagonists (setrons, CVN058 and the antidepressant vortioxetine) for CIAS and negative, positive and total symptoms. 12 active- vs. placebo-arm comparisons across 730 participants met the inclusion criteria. Meta-analyses of both negative symptoms [Cohen's d = -0.52 (95%CI: -0.78, -0.27), p = 0.012] and CIAS [Cohen's d = -0.53 (95%CI: 0.09, 0.97), p = 0.02] support a significantly greater effect for active drug at a moderate effect size. The results support the potential utility not only of "setron" type 5-HT3R antagonists, but also of vortioxetine, which has significant 5-HT3R antagonist properties along with more general anti-depressant features. Results argue for definitive multicenter studies of adjunctive 5-HT3R antagonists in schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- New York State Psychiatric Institute, New York, NY, USA.
- Columbia University, College of Physicians and Surgeons, New York, NY, USA.
- Nathan Kline Institute, Orangeburg, NY, USA.
- New York State Psychiatric Institute, New York, NY, USA. Joshua.kantrowitz@nyspi.columbia.edu.
- Columbia University, College of Physicians and Surgeons, New York, NY, USA. Joshua.kantrowitz@nyspi.columbia.edu.
- Nathan Kline Institute, Orangeburg, NY, USA. Joshua.kantrowitz@nyspi.columbia.edu.
Förderung
- internal funding (NYSPI) to JTK
Zitieren
APA
Mayer, M. R., Choo, T. H., Javitt, D. C., & Kantrowitz, J. T. (2026). Serotonin type 3 receptor (5-HT3R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology, 51(10), 1891-1897. https://doi.org/10.1038/s41386-026-02467-2
Vancouver
Mayer MR, Choo TH, Javitt DC, Kantrowitz JT. Serotonin type 3 receptor (5-HT3R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology. 2026;51(10):1891-1897. doi:10.1038/s41386-026-02467-2
BibTeX
@article{Mayer2026,
author = {Mayer, Megan R and Choo, Tse-Hwei and Javitt, Daniel C and Kantrowitz, Joshua T},
title = {Serotonin type 3 receptor (5-HT3R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis},
journal = {Neuropsychopharmacology},
year = {2026},
volume = {51},
number = {10},
pages = {1891--1897},
doi = {10.1038/s41386-026-02467-2}
}
EUVIMED